pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Foundayo
drug · small molecule
save

orforglipron calcium

Marketedupdated 6mo ago
by Eli Lilly and Co🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 7
  • drugFOUNDAYO8 co-mentions · 2 sources
  • tagSmall Molecule4 co-mentions · 2 sources
  • tagApproval4 co-mentions · 1 sources
  • companyEli Lilly and Co2 co-mentions · 1 sources
  • drugOzempic2 co-mentions · 1 sources
  • drugWegovy2 co-mentions · 1 sources
  • drugWegovy Pill2 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Unknown (across all indications), with 3 investigational indications.

indications

investigational
Type 2 DiabetesObesity

all catalysts(1)

approval · 1
Apr 1, 2026
approval
$LLY1382.75-2.32%
8mo ago
FOUNDAYO (ORFORGLIPRON CALCIUM) — FDA approval
orforglipron calcium
→

News(10)

  • Blackstone bets $1.5B on Pfizer’s obesity drug
    The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.
    biopharma_dive · 6d ago
  • Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
    Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about th…
    biospace · 8d ago
  • FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
    Twelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.
    biospace · 9d ago
  • Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3
    If approved, the oral GLP-1 would be Eli Lilly’s second marketed drug for obstructive sleep apnea after the GIP/GLP-1 injectable Zepbound secured the first approval in the space in December 2024.
    biospace · 9d ago
  • STAT+: Heart association meeting’s readout is trending ‘neutral’
    The theme of the American Heart Association meetings was "neutral" results. Yet no one wants to stop pursuing inflammation or Lp(a) lowering.
    stat · 9d ago
  • STAT+: Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in studies
    Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in two late-stage studies, but it doesn’t appear as effective as Lilly’s injectable drug Zepbound.
    stat · 9d ago
  • Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
    The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.
    biopharma_dive · 12d ago
  • This week in charts: 3 drug launches Wall Street is watching
    The latest installment in BioPharma Dive’s visualization-focused series features a look at investors’ response to a trio of medicines highlighted in quarterly earnings this week.
    biopharma_dive · 13d ago
  • Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
    The drug’s third-quarter sales numbers came in well above consensus estimates, widening Novo’s early edge over Eli Lilly in the latest battleground for weight loss medicines.
    biopharma_dive · 14d ago
  • Novo, Lilly battle for oral GLP-1 dominance with data tit for tat
    Novo CEO Mike Maziar Doustdar insists that his company is ahead of fierce rival Eli Lilly as oral Wegovy rises to 8 million total prescriptions since its January launch.
    biospace · 15d ago
view all news mentions →
brand
Foundayo
generic
orforglipron calcium
MOA
12.1 Mechanism of Action FOUNDAYO is a GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor. GLP-1 is a physiological regulator of appetite and caloric intake. GLP-1 receptors are present in brain regions that regulate appetite. In animal studies, orforglipron distributed to and activated neurons in brain regions that regulate appetite and food intake.
indication
Type 2 Diabetes
phase
marketed
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?